United States

GlaxoSmithKline PLC (GSK)

GSK on New York Consolidated

26 Apr 2017
Change (% chg)

$-0.79 (-1.89%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

GSK files regulatory submission in U.S. for COPD treatment
Monday, 21 Nov 2016 02:11am EST 

Glaxosmithkline Plc : Files regulatory submission in US for once-daily closed triple combination therapy ff/umec/vi for patients with copd .This follows announcement earlier this year of plans to bring forward timing of us filing from first half of 2018..  Full Article

Fimbrion, GSK to develop novel antibacterial therapy for UTIs
Tuesday, 25 Oct 2016 09:45am EDT 

Fimbrion Therapeutics Inc:Fimbrion - co and GSK to develop novel antibacterial therapy for urinary tract infections.  Full Article

Glaxo to pay $20 mln to resolve SEC charges
Friday, 30 Sep 2016 02:15pm EDT 

GlaxoSmithKline PLC : SEC says GlaxoSmithKline PLC to pay $20 million to settle foreign corrupt practices act charges . SEC says civil penalty resolves charges that glaxo's China-based units engaged in pay-to-prescribe schemes to boost sales . SEC says glaxo did not admit or deny wrongdoing . SEC says glaxo's accounting controls failed to prevent schemes, and improper payments were not accurately reflected in its books.  Full Article

GlaxoSmithKline appoints new consumer healthcare CEO
Thursday, 29 Sep 2016 07:40am EDT 

GlaxoSmithKline Plc : GlaxoSmithKline plc appoints Brian McNamara as CEO of GSK consumer healthcare . McNamara succeeds Emma Walmsley who was last week appointed GSK CEO designate succeeding Sir Andrew Witty as GSK CEO . McNamara is currently head of Europe & Americas at GSK consumer healthcare Further company coverage: [GSK.L] (Bengaluru Newsroom) ((+91 806 749 1136;)).  Full Article

Aspen Pharmacare says GSK sells remaining stake in co
Thursday, 29 Sep 2016 03:05am EDT 

Aspen Pharmacare Holdings Ltd : GSK completed an accelerated bookbuild for disposal of its remaining shareholding in aspen .Disposal in no way affects ongoing collaboration between aspen and GSK in South Africa.  Full Article

GSK gets 477 mln stg gross proceeds from Aspen Pharmacare stake sale
Thursday, 29 Sep 2016 02:54am EDT 

Glaxosmithkline Plc :Gross proceeds of Aspen transaction are equivalent to £477 million.  Full Article

GSK says to sell remaining stake in Aspen Pharmacare
Wednesday, 28 Sep 2016 11:19am EDT 

GlaxoSmithKline Plc : GSK intends to sell remaining holding in Aspen . Intends to sell its remaining stake in Aspen Pharmacare Holdings Ltd . Offer price will be determined by means of an accelerated bookbuild offering process which is to start immediately .Offering is expected to comprise up to 28.2 million Aspen ordinary shares equivalent to 6.2 pct of Aspen's ordinary share capital.  Full Article

GSK, Oncodesign announce agreement for Oncodesign's Acquisition of GSK's Research Centre in France
Wednesday, 28 Sep 2016 01:30am EDT 

Oncodesign SA : Says GSK will provide EUR35 million support over a four year period . To use funding to integrate site, its capabilities into its business and ensure continued employment of transferring staff over the period .GSK, Oncodesign announce agreement for Oncodesign's acquisition of GSK's research centre in France.  Full Article

Oncodesign to buy François Hyafil research centre from GSK
Wednesday, 28 Sep 2016 01:30am EDT 

Oncodesign Sa : GSK and oncodesign have signed an agreement for Oncodesign to acquire François Hyafil research centre from GSK . Agreement is expected to become unconditional and effective by or on 1st December 2016 .Under terms of agreement, GSK will provide eur 35 million support over a four year period.  Full Article

Janssen Biotech submits application for approval of sirukumab in U.S. for rheumatoid arthritis
Friday, 23 Sep 2016 08:00am EDT 

Janssen Biotech Inc:Janssen submits application seeking approval of sirukumab in United States for rheumatoid arthritis.  Full Article

More From Around the Web

UPDATE 2-New GlaxoSmithKline CEO wants fewer, bigger new drug launches

* Q1 adjusted EPS 25.0 pence vs consensus 24.5p (Adds analyst comment, latest shares)